Form 4: Recursion Pharmaceuticals CEO Executes Stock Transactions Under 10b5-1 Plan

Recursion Pharmaceuticals CEO, Christopher Gibson, executed multiple transactions involving the conversion and sale of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• Christopher Gibson, CEO of Recursion Pharmaceuticals, engaged in several transactions involving the company's stock.
• On November 13th and 14th, 2024, Mr. Gibson converted 20,000 shares of Class B Common Stock into Class A Common Stock on each day.
• Simultaneously, he sold 20,000 shares of Class A Common Stock on each of those days at prices of $7.74 and $7.35 respectively.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Mr. Gibson directly owns 762,656 shares of Class A Common Stock.
• He also indirectly controls a significant number of shares through various entities, including LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
• Mr. Gibson also holds multiple stock options with varying exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative in itself. The sentiment is neutral.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.

Risks

• The sale of shares by the CEO could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine filing for insider transactions and is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid any appearance of impropriety.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• These plans allow insiders to sell shares without being accused of trading on non-public information.
• The volume of shares sold by Mr. Gibson is not unusual for a CEO, and the prices are within the typical range for the company's stock.

Stakeholder Impact

• The sale of shares by the CEO could potentially cause a slight decrease in the stock price, impacting shareholders.

Key Dates

Keywords

insider trading, Form 4, stock sale, Rule 10b5-1, Recursion Pharmaceuticals, Christopher Gibson, stock options, Class A Common Stock, Class B Common Stock